scholarly journals Transglutaminase 2 at the Crossroads between Cell Death and Survival

Author(s):  
Mauro Piacentini ◽  
Manuela D'Eletto ◽  
Laura Falasca ◽  
Maria Grazia Farrace ◽  
Carlo Rodolfo
FEBS Letters ◽  
2005 ◽  
Vol 579 (15) ◽  
pp. 3297-3302 ◽  
Author(s):  
László Fésüs ◽  
Zsuzsa Szondy

2005 ◽  
Vol 4 (9) ◽  
pp. 1293-1302 ◽  
Author(s):  
Liya Yuan ◽  
Kihang Choi ◽  
Chaitan Khosla ◽  
Xiao Zheng ◽  
Ryuji Higashikubo ◽  
...  

Cells ◽  
2021 ◽  
Vol 10 (7) ◽  
pp. 1842
Author(s):  
Hideki Tatsukawa ◽  
Kiyotaka Hitomi

Transglutaminase 2 (TG2) is a ubiquitously expressed enzyme catalyzing the crosslinking between Gln and Lys residues and involved in various pathophysiological events. Besides this crosslinking activity, TG2 functions as a deamidase, GTPase, isopeptidase, adapter/scaffold, protein disulfide isomerase, and kinase. It also plays a role in the regulation of hypusination and serotonylation. Through these activities, TG2 is involved in cell growth, differentiation, cell death, inflammation, tissue repair, and fibrosis. Depending on the cell type and stimulus, TG2 changes its subcellular localization and biological activity, leading to cell death or survival. In normal unstressed cells, intracellular TG2 exhibits a GTP-bound closed conformation, exerting prosurvival functions. However, upon cell stimulation with Ca2+ or other factors, TG2 adopts a Ca2+-bound open conformation, demonstrating a transamidase activity involved in cell death or survival. These functional discrepancies of TG2 open form might be caused by its multifunctional nature, the existence of splicing variants, the cell type and stimulus, and the genetic backgrounds and variations of the mouse models used. TG2 is also involved in the phagocytosis of dead cells by macrophages and in fibrosis during tissue repair. Here, we summarize and discuss the multifunctional and controversial roles of TG2, focusing on cell death/survival and fibrosis.


2012 ◽  
Vol 33 (3) ◽  
pp. 235-241 ◽  
Author(s):  
Sung-Yup Cho ◽  
Eui Man Jeong ◽  
Jin-Haeng Lee ◽  
Hyo-Jun Kim ◽  
Jisun Lim ◽  
...  

2020 ◽  
Vol 21 (7) ◽  
pp. 2493 ◽  
Author(s):  
Soo-Youl Kim ◽  
Jeffrey W. Keillor

In a recent report, no significance of transglutaminase 2 (TGase 2) was noted in the analyses of expression differences between normal and clear cell renal cell carcinoma (ccRCC), although we found that knock down of TGase 2 induced significant p53-mediated cell death in ccRCC. Generally, to find effective therapeutic targets, we need to identify targets that belong specifically to a cancer phenotype that can be differentiated from a normal phenotype. Here, we offer precise reasons why TGase 2 may be the first therapeutic target for ccRCC, according to several lines of evidence. TGase 2 is negatively regulated by von Hippel-Lindau tumor suppressor protein (pVHL) and positively regulated by hypoxia-inducible factor 1-α (HIF-1α) in renal cell carcinoma (RCC). Therefore, most of ccRCC presents high level expression of TGase 2 because over 90% of ccRCC showed VHL inactivity through mutation and methylation. Cell death, angiogenesis and drug resistance were specifically regulated by TGase 2 through p53 depletion in ccRCC because over 90% of ccRCC express wild type p53, which is a cell death inducer as well as a HIF-1α suppressor. Although there have been no detailed studies of the physiological role of TGase 2 in multi-omics analyses of ccRCC, a life-long study of the physiological roles of TGase 2 led to the discovery of the first target as well as the first therapeutic treatment for ccRCC in the clinical field.


Author(s):  
Soner Gundemir ◽  
Gozde Colak ◽  
Julianne Feola ◽  
Richard Blouin ◽  
Gail V.W. Johnson

Sign in / Sign up

Export Citation Format

Share Document